

## Interpace Pharma Solutions is a leader in enabling precision medicine for immuno-oncology and genomic medicine through diagnostics, molecular markers, and data solutions.

Interpace Pharma Solutions (IPS) provides laboratory services supporting clinical trials and advanced diagnostic development across immuno-oncology, hematology, and solid tumors. Our scientific, medical, and regulatory experts help our biopharma and diagnostic clients accelerate their clinical development programs. Through our extensive technology portfolio and agile approach, we provide a broad suite of applications in support of our industry partners.

### IPS's Solution Suite of Molecular Diagnostics

IPS offers full molecular diagnostics capabilities utilizing various platforms to accommodate a variety of analyses. Our state-of-the-art molecular laboratory is technology-agnostic and equipped with innovative platforms, covering next generation sequencing (NGS), NanoString® services, liquid biopsies, etc. We are a certified service provider for various companies, such as Invitae® (ArcherDx), etc., and offer full NGS capabilities with both Illumina® and Thermo Fisher platforms, providing a mix of proprietary panels and off-the-shelf assays. IPS's comprehensive menu of validated assays is ready for direct use in your oncology programs. In addition, our highly experienced staff ensures the development and validation of new and custom assays both for heme malignancies and solid tumors.

This is a representative listing of available test offerings.  
Interpace Pharma Solutions builds custom solutions to meet client specifications.

## NGS Heme Panels

### Focus::Myeloid™ – [50 genes]\*

ABL1, ASXL1, ATRX, BCOR, BRAF, CALR, CBL, CBLB, CBLC, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KMT2A (MLL), KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1

CUX1, CXCR4, DCK, DDX41, DHX15, DNMT3A, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, LUC7L2, MAP2K1, MPL, MYC, MYD88, NF1, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PPM1D, PTEN, PTPN11, RAD21, RBBP6, RPS14, RUNX1, SETBP1, SF3B1, SH2B3, SLC29A1, SMC1A, SMC3, SRSF2, STAG2, STAT3, TET2, TP53, U2AF1, U2AF2, WT1, XPO1, ZRSR2

### VARIANTplex® Myeloid – [75 genes]\*

ABL1, ANKRD26, ASXL1, ATRX, BCOR, BCORL1, BRAF, BTK, CALR, CBL, CBLB, CBLC, CCND2, CDC25C, CDKN2A, CEBPA, CSF3R,

### Focus::CLL™ – [7 genes]\*

ATM, BIRC3, CARD11, MYD88, NOTCH1, SF3B1, TP53

## NGS Solid Tumor Panels

### Focus::OncoPrint™\*

#### DNA panel [35 genes – hotspot mutations]

AKT1, ALK, AR, BRAF, CDK4, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FGFR2, FGFR3, GNA11, GNAQ, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, PDGFRA, PIK3CA, RAF1, RET, ROS1, SMO

#### DNA panel [19 genes – focal CNV gains]

ALK, AR, BRAF, CCND1, CDK4, CDK6, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, FGFR4, KIT, KRAS, MET, MYC, MYCN, PDGFRA, PIK3CA

#### RNA panel - [23 genes – fusion drivers]

ABL1, AKT3, ALK, AXL, BRAF, EGFR, ERBB2, ERG, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, PDGFRA, PPARG, RAF1, RET, ROS1

(continued on next page...)

\*These assays have been analytically validated to CLIA standards. Individual markers contained on each assay would require further clinical validation to be used for in vitro diagnostic purposes.

All trademarks are the property of their respective owners.



## NGS Solid Tumor Panels (continued)

### Oncomine™ Comprehensive Assay v3 – [161 genes]<sup>†</sup>

#### DNA [hotspot genes]

AKT1, AKT2, AKT3, ALK, AR, ARAF, AXL, BRAF, BTK, CBL, CCND1, CDK4, CDK6, CHEK2, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ERCC2, ESR1, EZH2, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, H3F3A, HIST1H3B, HNF1A, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KDR, KIT, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAP2K4, MAPK1, MAX, MDM4, MED12, MET, MTOR, MYC, MYCN, MYD88, NFE2L2, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CB, PIK3CA, PPP2R1A, PTPN11, RAC1, RAF1, RET, RHEB, RHOA, ROS1, SF3B1, SMAD4, SMO, SPOP, SRC, STAT3, TERT, TOP1, U2AF1, XPO1

#### DNA [full-length genes]

ARID1A, ATM, ATR, ATRX, BAP1, BRCA1, BRCA2, CDK12, CDKN1B, CDKN2A, CDKN2B, CHEK1, CREBBP, FANCA, FANCD2, FANCI, FBXW7, MLH1, MRE11, MSH6, MSH2, NBN, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, PALB2, PIK3R1, PMS2, POLE, PTCH1, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RNF43, RB1, SETD2, SLX4, SMARCA4, SMARCB1, STK11, TP53, TSC1, TSC2

#### DNA [copy number genes]

AKT1, AKT2, AKT3, ALK, AXL, AR, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, EGFR, ERBB2, ESR1, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, IGF1R, KIT, KRAS, MDM2, MDM4, MET, MYC, MYCL, MYCN, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CB, PIK3CA, PPARG, RICTOR, TERT

#### RNA [gene fusions (inter- and intragenic)]

AKT2, ALK, AR, AXL, BRCA1, BRCA2, BRAF, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PRKACA, PRKACB, PTEN, PPARG, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSP02, RSP03, TERT

#### LIQUIDPlex™ ctDNA 28<sup>†</sup>

AKT1, ALK, AR, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ESR1, FGFR1, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MAP2K2, MET, MTOR, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, RET, ROS1, SMAD4, TP53

## NanoString®

IPS offers all of NanoString's panels on the company menu and has a collaborative relationship with the company to integrate custom content and panel designs for our clients.

Now Available  
GeoMx® Digital Spatial Profiling

## Additional Platforms and Equipment

Sanger Sequencing  
Fragment Analysis  
Pyrosequencing

qPCR  
Luminex (Nucleic Acid)

\*These assays have been analytically validated to CLIA standards. Individual markers contained on each assay would require further clinical validation to be used for in vitro diagnostic purposes.

<sup>†</sup>RUO only

All trademarks are the property of their respective owners.

